Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib.

NPJ Precis Oncol · 2026 · PMC12982539 · PMID 41644647

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although ORR and mPFS were numerically higher in the baseline MET-specific alterations negative, these differences did not reach statistical significance, indicating limited prognostic value of baseline ctDNA alone.

also in 111,027 other papers

showed a trendno p-value reported

Patients achieving ctDNA negativity of canonical alterations showed a trend toward superior outcomes, with a numerically threefold higher ORR but no significant difference when compared to those with ctDNA positivity (60.0%, 95% CI: 35.2–84.8% vs. 20.0%, 95% CI: 5.0–71.6%, p = 0.303).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.